Harvard Business Review

JANUARY 31, 2013

Second, we see a raft of innovations that will alter how products are designed, manufactured and sold — everything from nanotechnologies to 3D printing. Then, manufacturing's most important role is as a driver of innovation, trade, and productivity. Innovations Are Changing The Way We Design Products.

Globalization 8

Globalization Supply Chain Pharmaceuticals McKinsey 8

Harvard Business Review

SEPTEMBER 19, 2013

Thinking beyond the bottom line was considered unfocused or, even worse, a disservice to shareholders. New problem-solving innovators and investors power this solution economy. Today, the landscape has changed dramatically. A new economy has emerged at the borderlands where traditional sectors overlap. Consider just a few data points.

Pharmaceuticals 10

Pharmaceuticals Marketing Politics Bottom-up 10

Harvard Business Review

MAY 18, 2015

Despite some early warnings, both the regulators and the company did not really follow up the case until it was too late. At this point – the tipping point — companies would hugely benefit if people speak up and use this information to correct the bad decisions they made. billion from a series of high-risk trades.

Compliance 8

Compliance Company Self-aware Ethics 8

Harvard Business Review

JULY 14, 2017

A recent survey on easing racial tensions at work by the Center for Talent Innovation found that “The workplace is one of few settings where we commonly interact across racial and ethnic lines.” Make work safe for discussion and conflict. I want us to stay civil and kind, but we have to be frank.” Do not tolerate incivility.

Diversity 8

Diversity Politics Survey Incubator 8

Harvard Business Review

FEBRUARY 4, 2013

Our research with members of the global C-suite, and with leading sustainability and innovation experts, has identified seven vectors of breakthrough change. Breakthrough requires an end to systemic inequities by opening up processes, information - and markets. Accelerating Customer Adoption at the Bottom of the Pyramid.

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

FEBRUARY 6, 2014

Moreover, reaching the ultimate level of chief executive is not just another move up the corporate ladder. And what was critical here, in our view, or at any major enterprise for that matter, is for the directors to take the time to watch the candidates in action and to drill down with bottoms up data. Lafley has described it.

CEO 8

CEO Bottom-up Strategic Fit Pharmaceuticals 8

Harvard Business Review

FEBRUARY 20, 2014

As collectibles go, magazines are at the bottom of the list. Why bring up an article in a dusty old magazine? If it were up to me, I’d put more resources into space exploration.) It’s not inconceivable that in the not-too-distant future, China will catch up with us in space. I just don’t buy it.

Intellectual Capital 8

Intellectual Capital Magazine Pharmaceuticals Creativity 8

Harvard Business Review

SEPTEMBER 5, 2013

Marissa Mayer, Yahoo''s CEO, ended the company''s work-from-home policy to foster a more collaborative, innovative environment. One of us (Jordan) had personal responsibility for setting up such a service in Pfizer - it became known as PfizerWorks, and its aim was simply to help employees be more effective in their jobs.

Productivity 8

Productivity Products Peer Review Short-term 8

Harvard Business Review

APRIL 19, 2016

has been an innovation superpower. Take a look at any significant innovation, such as an iPhone , and you’ll find that most, if not all, of the technology came from some government program. In the pharmaceutical industry, the monitoring process can be incredibly elaborate. vincent tsui FOR HBR. Since World War II, the U.S.

Innovation 8

Innovation Company Competitive Advantage Venture Funding 8

Harvard Business Review

SEPTEMBER 3, 2013

Hilde Dach, the former chief scientist at drug-development start-up Genbac and now a team leader at German pharmaceuticals maker Caliska, which had acquired Genbac, could read disappointment in the face of Johan Greve, the Caliska division head who was her boss. We can get them up," she said encouragingly. "It Hilde turned away.

Case Study 8

Case Study Pharmaceuticals Bottom-up Marketing 8

Strategy Driven

JANUARY 24, 2011

Closing the Execution Gap : How Great Leaders and Their Companies Get Results by Richard Lepsinger If an organization can’t execute its plans and initiatives, nothing else matters: not the most solid, well thought-out strategy, not the most innovative business model, not even technological breakthroughs that could transform an industry.

Execution 67

Execution Company 360-Degree Feedback Cooper 67

Harvard Business Review

OCTOBER 27, 2014

I studied large-scale change and innovation efforts in 56 randomly selected companies in the high-tech, retail, pharmaceutical, banking, automotive, insurance, energy, non-profit, and health care industries. Taylor created a sense of urgency and then kept up the pace with tight deadlines.

Middle Management 11

Middle Management Six Sigma Taylorism Taylor 11

Harvard Business Review

OCTOBER 26, 2017

Two decades later, an incredible tool is shoring up the foundations of social at the level of every transaction—blockchain. A blockchain could record registered attestations important for supply chain participants, producers, and consumers, including ensuring source farms use sustainable practices and live up to fair trade practices.

Supply Chain 8

Supply Chain Content Power Transportation 8

Harvard Business Review

SEPTEMBER 11, 2014

have increased by 6x (from 100k to 600k annually) and, worldwide, start-ups have increased from 10 million to almost 100 million per year. For example, when Rent the Runway founder Jenn Hyman came up with the idea to rent designer dresses over the internet , demand uncertainty was high because no one else was offering this type of service.

Uncertainty 20

Uncertainty Industry Bottom-up Technology 20

Harvard Business Review

JUNE 20, 2017

Firms in innovation-driven industries, such as pharmaceuticals and medical devices, have long supported greater standardization across borders, with stronger intellectual property protections and enforcement of regulatory standards. The bottom line is, multinationals will not know what will be in the final agreement for years.

Supply Chain 8

Supply Chain Depreciation Uncertainty Marketing 8

Harvard Business Review

FEBRUARY 24, 2017

Holding up a bill in committee or working with others to stall legislation may be difficult to tie to any single person, while other actions can be defended on alternative premises , like coincidence (the idea that conflicts are inevitable among the myriad issues facing Congress) or even that they are based on a stockbroker’s advice.

Conflict of Interest 8

Conflict of Interest Committee Collins Politics 8